Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Sep 17, 2022 1:07pm
189 Views
Post# 34969020

RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo Clinic

RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo ClinicThanks to Noteable, as always.

Science Translational Medicine is perhaps the world's premier journal in its specific domain.

The total market for CAR-T therapy:
The market is expected to grow from $1,037.0 million in 2020 to $3,150.0 million in 2025 at a rate of 24.9%. The growth is mainly due to an increased prevalence of cancer and increased awareness about the therapy. The market is expected to stabilize $ 6,100 million in 2030.

What the article in Science implies is that pela makes CAR-T work a lot better.

If the whole world of big pharma agrees with these findings, our potential market for pela must be expanding by the month. Again, I ask myself: why have we not been bought out yet? My best answer: we are waiting for panc results.



<< Previous
Bullboard Posts
Next >>